Combined Treatment with Shuyu Pills and Everolimus Suppresses Triple-Negative Breast Cancer Growth via the PI3K/AKT/mTOR Pathway
Breast Cancer: Targets and Therapy · 2026-03 · Volume 18 · 1-17
DOI: 10.2147/bctt.s580570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer: Targets and Therapy, 2026-03. Verfasst von Jingzhe Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
- Traditional Chinese Medical Department, Zunyi Medical and Pharmaceutical College, Zunyi, Guizhou, People's Republic of China.
- Department of Pharmacy, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
- Department of Traditional Chinese Medicine, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
ORCID-Profile: Jingzhe Zhao, Su Xie
Zitieren
APA
Zhao, J., Luo, X., Li, H., Cheng, Y., Lin, X., & Xie, S. (2026). Combined Treatment with Shuyu Pills and Everolimus Suppresses Triple-Negative Breast Cancer Growth via the PI3K/AKT/mTOR Pathway. Breast Cancer: Targets and Therapy, Volume 18, 1-17. https://doi.org/10.2147/bctt.s580570
Vancouver
Zhao J, Luo X, Li H, Cheng Y, Lin X, Xie S. Combined Treatment with Shuyu Pills and Everolimus Suppresses Triple-Negative Breast Cancer Growth via the PI3K/AKT/mTOR Pathway. Breast Cancer: Targets and Therapy. 2026;Volume 18:1-17. doi:10.2147/bctt.s580570
BibTeX
@article{Zhao2026,
author = {Zhao, Jingzhe and Luo, Xiaoshan and Li, Huan and Cheng, Yu and Lin, Xiangping and Xie, Su},
title = {Combined Treatment with Shuyu Pills and Everolimus Suppresses Triple-Negative Breast Cancer Growth via the PI3K/AKT/mTOR Pathway},
journal = {Breast Cancer: Targets and Therapy},
year = {2026},
volume = {Volume 18},
pages = {1--17},
doi = {10.2147/bctt.s580570}
}
EUVIMED